Amendment of exclusion criterion related to recommended washout of systemic immunosuppressive or immunomodulatory drugs Addition of lower weight limit Amendment of exclusion criterion related to anaemia Revision of guidance regarding the adequacy of double barrier contraceptive methods Revision of liver function test criteria in relation to the permanent discontinuation of IMP Establishment of consistent safety follow up for all study participants that covers 4 to 5 half-lives of IMP. Revision of code break process in the event of a medical emergency

Corrected previous omission in synopsis Clarification that change in immunohistochemistry of K16 would be measured by a qualified pathologist Clarification that Cmax would be determined after all infusions. Reduction of Follow-up Period to Day 253 for all patients Clarification of the personnel who would be blinded Reduction of washout period for systemic Cyclosporin A to within 3 weeks of Baseline Clarification of Total bilirubin >ULN (except in circumstances where Gilbert’s Syndrome can be confirmed) Clarification of the duration of birth control measures Clarification of the rules for replacement of patients and dosing Clarification of rules around dosing if a dose needs to be temporarily discontinued Investigator Assessments to be performed by the same Assessor One repeat of safety laboratory tests and vital signs and more flexibility for rescreening Clarification of timing of baseline biopsy Clarification of the type of assay to be used for Inflammatory Proteomic Analysis Reduction in blood volume required during study extension Further clarification of the FAS population Further clarification and detail provided on PK analysis Where previously used incorrectly the term Monitor or Medical Monitor was replaced by Study Monitor Replacement of Amendment 1 by Summary of Protocol Amendments